Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853734 | 1.00 | ESR1 (0.50) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL13807784 | 1.00 | ESR1 (0.50) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL4191325 | 1.00 | ESR1 (0.50) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL6853827 | 0.99 | ESR1 (0.49) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL6849122 | 0.91 | ESR1 (0.50) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL6849270 | 0.91 | ESR1 (0.50) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL3864635 | 0.91 | ESR1 (0.50) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL6849120 | 0.90 | ESR1 (0.49) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL7106646 | 0.90 | ESR1 (0.49) | ESR1HSD17B10AKR1C3TSHRMAPK1 | |
| SCHEMBL8381243 | 0.90 | ESR1 (0.49) | ESR1HSD17B10AKR1C3TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2010139411-A2 | 17β-ALKYL-17α-OXY-ESTRATRIENES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | WO | disclosed |
| EP-2258375-A1 | 17B-alkyl-17alpha-oxy-estratrienes | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009074313-A1 | METHOD FOR THE AROMATIZATION OF 19-NOR-ANDROST-4-EN-3-ONES INTO ESTRA-1,3,5(10)-TRIENES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156843-A1 | PROCESS FOR AROMATIZING 19-NORANDROST-4-EN-3-ONES TO ESTRA-1,3,5(10)-TRIENES | BAYER SCHERING PHARMA AG (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156843-A1 | PROCESS FOR AROMATIZING 19-NORANDROST-4-EN-3-ONES TO ESTRA-1,3,5(10)-TRIENES | BAYER SCHERING PHARMA AG (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2070942-A1 | Method for aromatising 19-nor-androst-4-en-3-ones to estra-1,3,5(10)-trienes | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156843-A1 | PROCESS FOR AROMATIZING 19-NORANDROST-4-EN-3-ONES TO ESTRA-1,3,5(10)-TRIENES | CYP19A1, HSD17B11, NR5A1 | ESR1 6/4885HSD17B10 37/4885AKR1C3 70/4885 |
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | CYP19A1, HSD17B11, CYP17A1 | ESR1 29/4885HSD17B10 58/4885AKR1C3 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.